New York, NY - September 11, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update....
New York, NY - September 1, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will participate in the upcoming investor conferences :...
Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim analysis expected in Q4 2026 Eti-cel:...
New York, NY - July 30, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026...
June 25, 2026 - New York (N.Y.) - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m....
New York, NY - June 11, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in...
New York, NY - June 9, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S....
New York, NY - May 20, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m....
New York, NY - May 12, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA)...
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) Full Phase 1 dataset expected in Q4 2026 Innovation Preclinical data on T ALE-based epigenetic editing, a non-DNA cutting approach, to be presented at...
New York, NY - May 4, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after...
New York, NY - April 27, 2026 - Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based epigenetic editing approach, that does not cut or permanently modify the DNA sequence,...